辅助抗PD-1治疗失败后转移性或不可切除黑色素瘤的免疫检查点抑制:EUMelaReg真实世界证据研究
基于欧洲黑色素瘤登记库(EUMelaReg),分析389例既往辅助抗PD-1治疗后失败、接受一线免疫检查点抑制(ICI)的不可切除或转移性黑色素瘤患者,并按1:1匹配3390例未接受过PD-1的对照。结果显示既往辅助抗PD-1治疗者客观缓解率(ORR)显著低于未接受过PD-1者(31.4% vs 48.8%,p<0.0001),中位无进展生存期(PFS)也显著更短,且该现象见于单药抗PD-1和Ipi/Nivo两种方案。
要点
- 既往辅助抗PD-1治疗后失败者一线ICI的ORR为31.4%,显著低于未接受过PD-1者的48.8%(p<0.0001)。
- 既往辅助抗PD-1治疗者中位PFS显著更短,且单药抗PD-1和Ipi/Nivo方案均如此。
- 辅助治疗后早期复发(治疗期间或结束后12周内)者ORR为28.5%、PFS为3.1个月,低于晚期复发者的37.7%和6.1个月。
核心结论
- 既往在辅助阶段接受过抗PD-1 ICI的转移性黑色素瘤患者,接受一线ICI(Ipi/Nivo或单药抗PD-1再治疗)的ORR显著更低、PFS显著更短。
研究设计与样本
- 基于欧洲黑色素瘤登记库(EUMelaReg)的真实世界证据研究。
- 分析389例既往辅助抗PD-1治疗后失败、接受一线ICI的不可切除或转移性黑色素瘤患者。
- 对照人群从3390例未接受过PD-1的病例池中,按一线ICI类型及多种预后因素1:1匹配选取。
- 疗效指标包括客观缓解率(ORR),PFS采用Kaplan-Meier和Cox回归分析。
主要发现
- 389例中303例(77.9%)一线接受Ipi/Nivo,86例(22.1%)接受抗PD-1单药。
- 既往辅助抗PD-1治疗者的ORR为31.4%,显著低于未接受过抗PD-1者的48.8%(p<0.0001)。
- Kaplan-Meier分析显示既往辅助抗PD-1治疗者中位PFS显著更短,且单药抗PD-1和Ipi/Nivo治疗均如此。
- 辅助治疗后早期复发(治疗期间或结束后12周内)者ORR为28.5%、PFS为3.1个月,晚期复发者分别为37.7%和6.1个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant immune checkpoint inhibition (ICI) with anti-PD-1 antibodies in high-risk resected melanoma has been shown to improve recurrence-free survival. It is unclear whether prior adjuvant anti-PD-1 therapy is associated with altered response to subsequent ICI treatment in the metastatic setting. METHODS: Using data from the European Melanoma Registry (EUMelaReg), we analyzed the efficiency of first-line (1L) ICI in non-resectable or metastatic melanoma after failure from prior adjuvant anti-PD-1 treatment. Both single-agent anti-PD-1 and combined anti-PD-1/CTLA-4 (Ipi/Nivo) 1L regimes were included in the analysis. We identified 389 patients receiving 1L ICI with prior adjuvant anti-PD-1 treatment. The control population was selected from a pool of 3390 PD-1-naive cases by 1:1 matching for the type of 1L ICI and various prognostic factors. As outcome measure, overall remission rates (ORR) were calculated and progression-free survival (PFS) was evaluated by Kaplan-Meier and Cox regression analysis. RESULTS: Out of 389 patients, 303 (77.9 %) received Ipi/Nivo and 86 (22.1 %) anti-PD-1 in 1L. ORR was significantly lower in pre-treated patients (31.4 %) as compared to anti-PD-1 naive patients (48.8 %; p < 0.0001). Kaplan-Meier analysis showed significantly shorter median PFS for pre-treated patients. This applied to both anti-PD-1 and Ipi/Nivo treatment. Patients with early recurrence from adjuvant treatment (during or up to 12 weeks after end of treatment) showed lower ORR (28.5 %) and shorter PFS (3.1 months) than those who recurred later (37.7 % and 6.1 months, respectively). CONCLUSIONS: Patients with metastatic melanoma, previously exposed to anti-PD-1 ICI in the adjuvant setting showed significantly lower ORR and shorter PFS to 1L ICI with either Ipi/Nivo or single-agent anti-PD-1 retreatment.
引用
- Weichenthal M, Ellebaek E, Mangana J, et al. Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study. Eur J Cancer. 2025. PMID: 40090216. doi:10.1016/j.ejca.2025.115339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。